A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Ependymoma
- Ewing Sarcoma
- High Grade Glioma
- Leukemia and Lymphoma
- Medulloblastoma
- Miscellaneous Brain Tumors
- Miscellaneous Solid Tumors
- Neuroblastoma
- Relapsed, Refractory Malignant Neoplasms
- Rhabdomyosarcoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 30 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04730349
- Collaborators
- Nektar Therapeutics
- Investigators
- Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Get Well Soon